NCT05163041View on ClinicalTrials.gov

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

BT7480

Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

DRUG

Nivolumab

Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion

Trial Locations (9)

10032

Columbia University Irving Medical Center, New York

19111

Fox Chase Cancer Center, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

44106

University Hospitals Cleveland Medical Center, Cleveland

52242

State University of Iowa, Iowa City

77030

MD Anderson Cancer Center, Houston

78229

START Center for Cancer Care, San Antonio

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

All Listed Sponsors
lead

BicycleTx Limited

INDUSTRY